Nabriva Therapeutics plc (NBRVF)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Nabriva Therapeutics plc (NBRVF) with AI Score 57/100 (Hold). Nabriva Therapeutics plc is a biopharmaceutical company focused on developing novel anti-infective agents for serious infections. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 15, 2026Nabriva Therapeutics plc (NBRVF) Healthcare & Pipeline Overview
Nabriva Therapeutics plc specializes in the development of innovative anti-infective agents, with a strong focus on addressing serious bacterial infections through its proprietary products and ongoing clinical trials.
Investment Thesis
Nabriva Therapeutics plc is positioned for potential growth driven by its innovative product pipeline and ongoing clinical trials. With a focus on serious infections, the company aims to expand the applications of its existing products, particularly XENLETA, which is being investigated for multiple indications. The market for antibiotics is projected to grow significantly, driven by rising antibiotic resistance and increasing infection rates, presenting a favorable environment for Nabriva's offerings. Additionally, the company's gross margin of 19.9% reflects its operational efficiency, although it faces challenges with a profit margin of -160.3%. Investors should monitor the progress of Nabriva's clinical trials and regulatory submissions as key indicators of future performance.
Based on FMP financials and quantitative analysis
Key Highlights
- Market Cap: $0.00B, indicating current valuation challenges.
- P/E Ratio: -0.00, reflecting ongoing losses.
- Profit Margin: -160.3%, showing significant operational losses.
- Gross Margin: 19.9%, indicating some level of operational efficiency.
- Beta: -0.84, suggesting lower volatility compared to the market.
Competitors & Peers
Strengths
- Strong focus on innovative anti-infective agents.
- Existing FDA-approved products generating initial revenue.
- Experienced leadership team with industry knowledge.
Weaknesses
- Current negative profit margin indicating operational challenges.
- Limited product portfolio compared to larger competitors.
- Small workforce may limit operational capacity.
Catalysts
- Upcoming: Results from ongoing clinical trials for XENLETA in new indications.
- Ongoing: Sales performance of SIVEXTRO and XENLETA in existing markets.
- Upcoming: Potential regulatory submissions for new product indications.
Risks
- Potential: Delays in clinical trial results impacting product timelines.
- Ongoing: Competition from larger pharmaceutical companies with more resources.
- Potential: Regulatory challenges that could hinder product approvals.
Growth Opportunities
- Expansion into Pediatric Markets: Nabriva is advancing XENLETA into Phase I clinical trials for pediatric infections, a segment with significant unmet needs. The pediatric antibiotic market is projected to grow at a CAGR of 6.5%, driven by rising infection rates among children. Successful development could lead to substantial revenue growth.
- Broadening XENLETA Indications: The ongoing clinical trials for XENLETA in treating sexually transmitted infections and cystic fibrosis could open new revenue streams. The global market for cystic fibrosis treatments is expected to reach $15 billion by 2027, providing Nabriva with a lucrative opportunity if XENLETA is approved for these indications.
- Development of CONTEPO: With CONTEPO targeting complicated urinary tract infections, Nabriva is tapping into a market projected to grow significantly. The urinary tract infection treatment market is expected to reach $6 billion by 2025, and successful trials could position Nabriva as a key player in this space.
- Strategic Partnerships: Collaborations with larger pharmaceutical companies for distribution and development could enhance Nabriva's market reach and financial stability. Partnerships can provide additional funding and resources for clinical trials, expediting the development process.
- Regulatory Approvals: Achieving regulatory approvals for its products can significantly enhance Nabriva's market position and revenue potential. The company is actively working on submissions that could lead to market entry and capture a share of the growing antibiotic market.
Opportunities
- Expansion into pediatric and other unaddressed markets.
- Potential for strategic partnerships to enhance development capabilities.
- Growing global demand for effective antibiotics.
Threats
- Intense competition from larger pharmaceutical companies.
- Regulatory hurdles that could delay product approvals.
- Market volatility affecting funding and investment.
Competitive Advantages
- Innovative product pipeline addressing significant unmet medical needs.
- Established market presence with FDA-approved products.
- Focus on serious infections positions Nabriva uniquely in the biotechnology landscape.
About NBRVF
Founded in 2005 and headquartered in Dublin, Ireland, Nabriva Therapeutics plc is a biopharmaceutical company dedicated to developing and commercializing novel anti-infective agents aimed at treating serious infections. The company initially operated under the name Nabriva Therapeutics Forschungs GmbH before rebranding in 2007. Nabriva's flagship products include SIVEXTRO, an oxazolidinone-class antibacterial specifically designed for treating acute bacterial skin and skin structure infections (ABSSSI), and XENLETA, a semi-synthetic pleuromutilin antibiotic available for both oral and intravenous administration. Beyond its marketed products, Nabriva is actively pursuing the development of XENLETA for a range of indications, including pediatric infections, sexually transmitted infections, cystic fibrosis, and various forms of pneumonia, among others. The company is also advancing CONTEPO, an epoxide antibiotic targeting complicated urinary tract infections, which is currently in Phase I clinical trials for peri-operative prophylaxis. Nabriva's innovative approach and commitment to addressing unmet medical needs position it as a notable player in the biotechnology sector.
What They Do
- Develop and commercialize novel anti-infective agents.
- Market SIVEXTRO for acute bacterial skin infections.
- Market XENLETA for various bacterial infections.
- Conduct clinical trials for new indications of existing products.
- Develop CONTEPO for complicated urinary tract infections.
- Focus on addressing unmet medical needs in serious infections.
Business Model
- Generate revenue through the sale of marketed products like SIVEXTRO and XENLETA.
- Pursue additional revenue streams from new product indications and clinical trials.
- Leverage partnerships for co-development and distribution agreements.
Industry Context
The biotechnology industry is characterized by rapid innovation and significant investment in research and development, particularly in the area of anti-infective agents. The global antibiotic market is expected to grow due to increasing antibiotic resistance and the rising prevalence of infectious diseases. Nabriva Therapeutics plc operates in a competitive landscape with several key players, including BIOCQ, CDXI, ELOX, HTGMQ, and MDVLQ, each focusing on various therapeutic areas. The demand for effective antibiotics continues to rise, presenting opportunities for Nabriva to expand its market presence.
Key Customers
- Healthcare providers and hospitals requiring effective anti-infective treatments.
- Pharmaceutical distributors and wholesalers.
- Patients suffering from serious bacterial infections.
Financials
Chart & Info
Nabriva Therapeutics plc (NBRVF) stock price: Price data unavailable
Latest News
No recent news available for NBRVF.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for NBRVF.
Price Targets
Wall Street price target analysis for NBRVF.
MoonshotScore
What does this score mean?
The MoonshotScore rates NBRVF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Leadership: H. Michael Hogan
CEO
H. Michael Hogan has extensive experience in the biopharmaceutical industry, having held various leadership roles in both public and private companies. He has a strong background in drug development and commercialization, with a focus on anti-infective therapies. Hogan holds a degree in Pharmacology and has been instrumental in guiding Nabriva's strategic direction.
Track Record: Under Hogan's leadership, Nabriva has successfully launched SIVEXTRO and advanced its product pipeline, positioning the company for future growth. His strategic decisions have focused on expanding clinical trials and exploring new therapeutic areas.
NBRVF OTC Market Information
The OTC Other tier represents stocks that do not meet the listing requirements of major exchanges like NYSE or NASDAQ. These stocks may have lower liquidity and higher volatility, which can affect trading conditions.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosures can lead to uncertainty about the company's performance.
- Lower trading volumes may result in higher volatility and price fluctuations.
- Potential for fraudulent schemes in the OTC market, requiring diligent research.
- Verify the company's financial health and operational metrics.
- Assess the progress of clinical trials and product approvals.
- Research the competitive landscape and market trends.
- Evaluate management's experience and track record.
- Review any available analyst reports or market commentary.
- Established product offerings with FDA approval.
- Presence of experienced leadership with industry expertise.
- Engagement in clinical trials demonstrating commitment to innovation.
NBRVF Healthcare Stock FAQ
What does Nabriva Therapeutics plc do?
Nabriva Therapeutics plc is a biopharmaceutical company focused on developing and commercializing novel anti-infective agents. Its key products include SIVEXTRO for treating acute bacterial skin infections and XENLETA, which is being explored for multiple indications, including pediatric infections and cystic fibrosis.
What do analysts say about NBRVF stock?
Analysts generally view Nabriva Therapeutics plc as a high-risk investment due to its ongoing operational losses and the challenges associated with developing new drugs. Key valuation metrics indicate a lack of profitability, and growth considerations focus on the outcomes of clinical trials and regulatory approvals.
What are the main risks for NBRVF?
Nabriva Therapeutics plc faces several risks, including potential delays in clinical trial results that could impact product timelines, ongoing competition from larger pharmaceutical companies, and regulatory challenges that may hinder product approvals. These factors contribute to the overall uncertainty surrounding the company's future performance.
What are the key factors to evaluate for NBRVF?
Nabriva Therapeutics plc (NBRVF) currently holds an AI score of 57/100, indicating moderate score. Key strength: Strong focus on innovative anti-infective agents.. Primary risk to monitor: Potential: Delays in clinical trial results impacting product timelines.. This is not financial advice.
How frequently does NBRVF data refresh on this page?
NBRVF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven NBRVF's recent stock price performance?
Recent price movement in Nabriva Therapeutics plc (NBRVF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Strong focus on innovative anti-infective agents.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider NBRVF overvalued or undervalued right now?
Determining whether Nabriva Therapeutics plc (NBRVF) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying NBRVF?
Before investing in Nabriva Therapeutics plc (NBRVF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited financial information available due to OTC classification.